Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.90 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245329 | 0.96 | HSD11B1 (0.97) | HSD11B1SLC6A3MEN1KMT2ASLC6A4 | |
| SCHEMBL16232160 | 0.93 | HSD11B1 (0.83) | HSD11B1SLC6A3MEN1KMT2A | |
| SCHEMBL18111428 | 0.85 | HSD11B1 (0.71) | HSD11B1MEN1KMT2ACACNA1G | |
| SCHEMBL17761217 | 0.84 | HSD11B1 (0.66) | HSD11B1SLC6A3MEN1KMT2ASLC6A4 | |
| SCHEMBL625584 | 0.83 | HSD11B1 (0.64) | HSD11B1SLC6A3MEN1KMT2ASLC6A4 | |
| SCHEMBL624643 | 0.82 | HSD11B1 (0.63) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14525408 | 0.82 | HSD11B1 (0.63) | HSD11B1KMT2A | |
| SCHEMBL625060 | 0.81 | HSD11B1 (0.62) | HSD11B1SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17761311 | 0.81 | HSD11B1 (0.71) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL627858 | 0.80 | HSD11B1 (0.60) | HSD11B1SLC6A3MEN1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| CN-103140476-A | Novel trpv3 modulators | ABBOTT LAB | 2013-06-05 | — | — | CN | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | HSD11B1 2616/4885SLC6A3 717/4885MEN1 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.